M C De Santis
Overview
Explore the profile of M C De Santis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ciniselli C, Verderio P, Duroni V, Baili P, Pizzamiglio S, de Braud F, et al.
Clin Transl Oncol
. 2025 Mar;
PMID: 40057925
Background: The reliability of core needle biopsy (CNB) for HER2-positive breast cancer is well established. However, data on HER2-low and the potential for inconsistencies with surgical samples are limited. Materials...
2.
Pizzamiglio S, Ciniselli C, de Azambuja E, Agbor-Tarh D, Moreno-Aspitia A, Suter T, et al.
Breast Cancer Res Treat
. 2024 Apr;
206(2):285-294.
PMID: 38689174
Purpose: The relevance of cardiotoxicity in the context of HER2-positive breast cancer is likely to increase with increasing patient treatment exposure, number of treatment lines, and prolonged survival. Circulating biomarkers...
3.
De Vincentis S, Greco C, Fanelli F, Decaroli M, Diazzi C, Mezzullo M, et al.
J Endocrinol Invest
. 2024 Apr;
47(11):2715-2730.
PMID: 38643322
Purpose: Sex steroids play a key role on male bone homeostasis and body composition (BC), their role in men living with HIV (MLWH) is less recognized. This study aimed at...
4.
La Rocca E, De Santis M, Silvestri M, Ortolan E, Valenti M, Folli S, et al.
J Cancer Res Clin Oncol
. 2022 Apr;
148(6):1543-1550.
PMID: 35396978
Purpose: Physical examinations and annual mammography (minimal follow-up) are as effective as laboratory/imaging tests (intensive follow-up) in detecting breast cancer (BC) recurrence. This statement is now challenged by the availability...
5.
Di Cosimo S, Depretto C, Miceli R, Baili P, Ljevar S, Sant M, et al.
J Cancer Res Clin Oncol
. 2022 Jan;
148(4):775-781.
PMID: 35037102
Background: Mammographic density (MD) is a risk factor for breast cancer (BC) development, and recurrence. However, its predictive value has been less studied. Herein, we challenged MD as a biomarker...
6.
Spaggiari G, Setti M, Tagliavini S, Roli L, De Santis M, Trenti T, et al.
J Endocrinol Invest
. 2020 Oct;
44(7):1501-1513.
PMID: 33123965
Purpose: To cope physical and/or psychological threats, the human body activates multiple processes, mediated by a close interconnection among brain, endocrine and inflammatory systems. The aim of the study was...
7.
La Rocca E, Lozza L, D Ippolito E, Dispinzieri M, Giandini C, Bonfantini F, et al.
Clin Transl Oncol
. 2020 Mar;
22(10):1802-1808.
PMID: 32128672
Purpose: To report acute toxicities in breast cancer (BC) patients (pts) recruited in a prospective trial and treated with accelerated partial-breast irradiation (APBI) using Volumetric Modulated Arc Therapy (VMAT) delivered...
8.
Meattini I, De Santis M, De Rose F, Desideri I, Franco P, Kaidar-Person O, et al.
Clin Oncol (R Coll Radiol)
. 2019 Aug;
32(1):e37-e38.
PMID: 31421912
No abstract available.
9.
De Santis M, La Rocca E, Meneghini E, Bregni G, Di Lorenzo G, Galli G, et al.
Clin Transl Oncol
. 2019 Aug;
22(5):786-792.
PMID: 31372896
Background: Primary tumor characteristics, which are readily available to all clinicians, may aid in selecting the optimal adjuvant therapy for patients with breast cancer (BC). Herein, we investigated the relationship...
10.
Roli L, Santi D, Belli S, Tagliavini S, Cavalieri S, De Santis M, et al.
J Endocrinol Invest
. 2017 Mar;
40(8):841-850.
PMID: 28326509
Purpose: Liquid-chromatography tandem mass-spectrometry (LC-MS/MS) was developed in parallel to Immunoassays (IAs) and today is proposed as the "gold standard" for steroid assays. Leydig cells of men with Klinefelter syndrome...